Revolution Medicines’ Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?
Revolution Medicines isn't profitable, but it has a drug with blockbuster potential.
·
The Motley Fool
Forget the 2026 Midterm Election Results. Warren Buffett’s Advice Makes This ETF a No-Brainer Buy
Elections come and go, but the right investing strategy can help you build lasting wealth.
·
The Motley Fool
This Dividend King Has Raised Its Payout Through Every Recession Since the 1950s. I’m Buying Before the End of the Year.
Procter & Gamble's dividend increase is one of the longest among U.S. companies and hasn't been interrupted by 10 recessions.
·
The Motley Fool
Billionaire Bill Ackman Has Been All-In on Uber. Is Now the Time to Buy the Stock?
Uber is Bill Ackman's largest position.
·
The Motley Fool
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines’ Groundbreaking Pancreatic Cancer Drug
Revolution Medicines has a big drug making headlines, and Royalty Pharma gets a bite of the action without doing anything at all.
·
The Motley Fool
Why Qualcomm Stock Fell 9% Despite Beating Earnings Estimates
Investors are worried the future may not be nearly as bright as management suggests, or arrive there as quickly as implied.
·
The Motley Fool
Tesla’s FSD (Supervised) Attach Rate Hit 75% on New Vehicles. Here’s Why That Single Number Could Matter More Than Robotaxi for the Stock in 2027.
Tesla's growing subscriber base deserves more attention.
·
The Motley Fool
